Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

MBX Biosciences (MBX) Income from Continuing Operations (2023 - 2026)

MBX Biosciences has reported Income from Continuing Operations over the past 4 years, most recently at 23517000.0 for Q1 2026.

  • Quarterly results put Income from Continuing Operations at 23517000.0 for Q1 2026, up 1.52% from a year ago — trailing twelve months through Mar 2026 was 86608000.0 (down 17.89% YoY), and the annual figure for FY2025 was 86971000.0, down 40.45%.
  • Income from Continuing Operations reached 23517000.0 in Q1 2026 per MBX's latest filing, down from 22062000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 8843000.0 in Q4 2023 and bottomed at 23880000.0 in Q1 2025.
  • Median Income from Continuing Operations over the past 4 years was 18142000.0 (2024), compared with a mean of 17401363.64.
  • The largest annual shift saw Income from Continuing Operations crashed 93.56% in 2025 before it increased 1.52% in 2026.
  • Over 4 years, Income from Continuing Operations stood at 8843000.0 in 2023, then crashed by 76.25% to 15586000.0 in 2024, then tumbled by 41.55% to 22062000.0 in 2025, then dropped by 6.6% to 23517000.0 in 2026.
  • Business Quant data shows Income from Continuing Operations for MBX at 23517000.0 in Q1 2026, 22062000.0 in Q4 2025, and 21618000.0 in Q3 2025.